Search Results

You are looking at 41 - 50 of 52 items for :

  • "myeloid growth factors" x
  • Refine by Access: All x
Clear All
Full access

Identifying Older Patients With Acute Myeloid Leukemia Who May Be Candidates for Reduced-Intensity Hematopoietic Cell Transplantation

Boglarka Gyurkocza and Frederick R. Appelbaum

use of highly effective antiemetics, antibiotics, antifungals, and myeloid growth factors, have changed practice. The weight loss, debility, erosive esophagitis, and aspiration pneumonia once common with induction chemotherapy in older patients are now

Full access

NCCN Task Force Report: Specialty Pharmacy

Rowena N. Schwartz, Kirby J. Eng, Deborah A. Frieze, Tracy K. Gosselin, Niesha Griffith, Amy Hatfield Seung, Jennifer M. Hinkel, Philip E. Johnson, Shirley A. Johnson, Edward C. Li, Audrea Hotsko Szabatura, and Michael K. Wong

agents, myeloid growth factors), oral anticancer agents, and, in some instances, parenteral chemotherapy or biologic agents. The proposed goals of specialty pharmacy include the optimization of pharmaceutical care outcomes through ensuring appropriate

Full access

Bone Cancer

J. Sybil Biermann, Douglas R. Adkins, Robert S. Benjamin, Brian Brigman, Warren Chow, Ernest U. Conrad III, Deborah A. Frassica, Frank J. Frassica, Suzanne George, Kenneth R. Hande, Francis J. Hornicek, G. Douglas Letson, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Neeta Somaiah, and Alan W. Yasko

with appropriate growth factor support for 12 to 24 weeks (see the NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors for growth factor support; to view the most recent version of these guidelines, visit the NCCN Web site at www

Full access

Developments in Molecular Testing and Biosimilars

Katy Winckworth-Prejsnar, Elizabeth A. Nardi, Lisa Korin Lentz, Jeffrey A. Crawford, C. Lyn Fitzgerald, and Robert W. Carlson

given disease setting. 30 , 31 Dr. Crawford, chair of the NCCN Myeloid Growth Factors Panel, discussed NCCN category of evidence designation without clinical trial data for all indications of filgrastim-sndz. Within the NCCN Guidelines, although

Full access

Pharmacotherapy for Chronic Myelogenous Leukemia: A Case-Based Approach

Stephen Harnicar

should be suspended and then reinitiated at a reduced dose of 300 mg. Data support the use of myeloid growth factors for patients with resistant neutropenia. 28 Grade 3 to 4 thrombocytopenia is managed similarly; therapy should be held until the platelet

Full access

NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020

Featured Updates to the NCCN Guidelines

Pamela Sue Becker, Elizabeth A. Griffiths, Laura M. Alwan, Kimo Bachiashvili, Anna Brown, Rita Cool, Peter Curtin, Shira Dinner, Ivana Gojo, Ashley Hicks, Avyakta Kallam, Wajih Zaheer Kidwai, Dwight D. Kloth, Eric H. Kraut, Daniel Landsburg, Gary H. Lyman, Ryan Miller, Sudipto Mukherjee, Shiven Patel, Lia E. Perez, Adam Poust, Raajit Rampal, Rachel Rosovsky, Vivek Roy, Hope S. Rugo, Sepideh Shayani, Sumithira Vasu, Martha Wadleigh, Kelly Westbrook, Peter Westervelt, Jennifer Burns, Jennifer Keller, and Lenora A. Pluchino

., Inc. Overview Myeloid growth factors (MGFs), such as granulocyte colony-stimulating factors (G-CSFs), are hematopoietic growth factors (HGFs) that regulate the growth and differentiation of cells in the myeloid lineage. 1 Pharmacologic G-CSFs, such as

Full access

Bone Cancer

J. Sybil Biermann, Douglas R. Adkins, Mark Agulnik, Robert S. Benjamin, Brian Brigman, James E. Butrynski, David Cheong, Warren Chow, William T. Curry, Deborah A. Frassica, Frank J. Frassica, Kenneth R. Hande, Francis J. Hornicek, Robin L. Jones, Joel Mayerson, Sean V. McGarry, Brian McGrath, Carol D. Morris, Richard J. O'Donnell, R. Lor Randall, Victor M. Santana, Robert L. Satcher, Herrick J. Siegel, Margaret von Mehren, Mary Anne Bergman, and Hema Sundar

include appropriate growth factor support (see the NCCN Guidelines for Myeloid Growth Factors for growth factor support; to view the most recent version of these guidelines, visit NCCN.org ). A list of specific chemotherapy regimens is available in “Bone

Full access

NCCN Task Force Report: Breast Cancer in the Older Woman

Robert W. Carlson, Susan Moench, Arti Hurria, Lodovico Balducci, Harold J. Burstein, Lori J. Goldstein, William J. Gradishar, Kevin S. Hughes, Mohammad Jahanzeb, Stuart M. Lichtman, Lawrence B. Marks, Joan S. McClure, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Mary Lou Smith, Neal S. Topham, Tiffany A. Traina, John H. Ward, and Eric P. Winer

evaluations of renal and hepatic functions, possible benefit of weekly dosing, and early use of myeloid growth factors were mentioned as important considerations. Some underexplored areas include evaluation of the pharmacokinetics and pharmacodynamics of

Full access

Small Cell Lung Cancer

Gregory P. Kalemkerian, Wallace Akerley, Paul Bogner, Hossein Borghaei, Laura Chow, Robert J. Downey, Leena Gandhi, Apar Kishor P. Ganti, Ramaswamy Govindan, John C. Grecula, James Hayman, Rebecca Suk Heist, Leora Horn, Thierry M. Jahan, Marianna Koczywas, Cesar A. Moran, Harvey B. Niell, Janis O'Malley, Jyoti D. Patel, Neal Ready, Charles M. Rudin, and Charles C. Williams Jr.

recommended therapy for patients with limited-stage disease (category 1). 49 , 50 , 58 In combination with thoracic radiotherapy, EP causes an increased risk of esophagitis, pulmonary toxicity, and hematologic toxicity. 59 The use of myeloid growth factors

Full access

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Jerald P. Radich, Michael Deininger, Camille N. Abboud, Jessica K. Altman, Ellin Berman, Ravi Bhatia, Bhavana Bhatnagar, Peter Curtin, Daniel J. DeAngelo, Jason Gotlib, Gabriela Hobbs, Madan Jagasia, Hagop M. Kantarjian, Lori Maness, Leland Metheny, Joseph O. Moore, Arnel Pallera, Philip Pancari, Mrinal Patnaik, Enkhtsetseg Purev, Michal G. Rose, Neil P. Shah, B. Douglas Smith, David S. Snyder, Kendra L. Sweet, Moshe Talpaz, James Thompson, David T. Yang, Kristina M. Gregory, and Hema Sundar

saturation, vitamin B 12 , and folate and correction of nutritional deficiencies if present is recommended for patients with grade 3/4 anemia. Red blood cell transfusions are indicated in symptomatic patients. Myeloid growth factor support can be used in